---
title: "CCHT's \"New Drug for Treating Male Children's Developmental Disorders\" Sparks Stock Price Surge; Company Responds: Project is Still in Early Stages"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277029426.md"
description: "CCHT's subsidiary Changchun Jinsai Pharmaceutical's clinical trial application for GenSci141 ointment has been approved, aimed at improving the issue of small penises in children. This is the world's first drug targeting this problem, and the market is highly concerned about the clinical progress of this project. CCHT stated that the project is still in the early stages, and there is currently no information available for external communication"
datetime: "2026-02-26T11:18:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277029426.md)
  - [en](https://longbridge.com/en/news/277029426.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277029426.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277029426.md) | [English](https://longbridge.com/en/news/277029426.md)


# CCHT's "New Drug for Treating Male Children's Developmental Disorders" Sparks Stock Price Surge; Company Responds: Project is Still in Early Stages

The clinical trial application for GenSci141 ointment by Changchun High-tech's subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. has been approved, with the indication for improving children's micropenis caused by various reasons. Data shows that this is the world's first drug targeting children's micropenis. Journalists noted that there is limited literature on children's micropenis, and there are global controversies regarding incidence, classification, surgical indications, and surgical age. This has drawn particular market attention to the clinical progress of GenSci141 ointment. Changchun High-tech stated that this project is still in the early stages, and there is currently no information available for external communication. (Everyday Economy)

### 相關股票

- [CCHT (000661.CN)](https://longbridge.com/zh-HK/quote/000661.CN.md)

## 相關資訊與研究

- [Changchun High-Tech Industry's Unit Gets Nod for GenSci141 Ointment Clinical Trial](https://longbridge.com/zh-HK/news/276832823.md)
- [A Look At Idorsia’s Valuation After Positive Pediatric Insomnia Phase 2 Results](https://longbridge.com/zh-HK/news/281255160.md)
- [Goodnites Launches Language of Bedwetting AAC System for Autistic Children](https://longbridge.com/zh-HK/news/281550275.md)
- [ZAWYA-PRESSR: Lime partners with Cippo Egypt to expand access to inclusive, high-quality education](https://longbridge.com/zh-HK/news/280912665.md)
- [11:33 ETFitness, Health and Wellness Experts Team Up to 'Get Fit for No Kid Hungry' with New On-Demand Initiative](https://longbridge.com/zh-HK/news/281213207.md)